COMMUNIQUÉS West-GlobeNewswire

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
19/08/2026
REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar [...]
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
19/08/2026
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients [...]
Solésence Reports Second Quarter 2026 Financial Results
19/08/2026
Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically driven health care [...]
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
19/08/2026
GENGLYCOS is the first gene therapy approval, and fifth FDA approval overall, for the company Approval provides a long-awaited first-ever option to reduce the burden of care associated with GSDIa Ultragenyx received a [...]
Picard Medical Reports Second Quarter 2026 Financial Results
19/08/2026
- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“ [...]
BC health research pursues precision, genetics-based care for three conditions
19/08/2026
VANCOUVER, British Columbia, Aug. 19, 2026 (GLOBE NEWSWIRE) -- A person’s DNA can help predict suitable treatments, medications and nutrition for them, leading to better personalized care. Three Genome British Columbia [...]
Increased outlook for 2026
19/08/2026
Novonesis increases its full year 2026 organic sales growth outlook from 5-7% to now 7-8% based on a stronger performance so far in the year and the expectations for the rest of the year. Following the stronger sales [...]
Announcement of share buyback program
19/08/2026
The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be completed by the end of [...]
Interim report H1 2026
19/08/2026
Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share buy-back program [...]
H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook
19/08/2026
COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the adjusted EBITDA margin [...]
Interim Report Q2 2026: Successful reception of Evolve3 headsets and gross margin improvement boding well for strong H2 2026
19/08/2026
Highlights The Enterprise division delivered organic revenue growth of -7%, while the organic revenue growth excl. FalCom ended at -3%. The development reflects continued strong growth in North America and APAC. The [...]
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
19/08/2026
FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability Approval based on results from [...]
Sofwave Surpasses One Million Treatments Worldwide; Milestone Treatment Performed in South Korea
19/08/2026
Global milestone reflects sustained physician utilization, patient adoption and the expanding reach of Sofwave’s SUPERB™ technology SAN CLEMENTE, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd. (TASE: [...]
Atsena Therapeutics Appoints Matt Pauls to Board of Directors
19/08/2026
Matt Pauls brings more than 25 years of biopharma leadership and rare disease clinical development and commercial expertise as Atsena advances its ocular gene therapy pipeline toward commercialization DURHAM, N.C., Aug [...]
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
19/08/2026
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data [...]
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
19/08/2026
WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
19/08/2026
- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary [...]
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies
19/08/2026
ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19/08/2026
Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion market with [...]

Pages